CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
265.25
0.7%
Market Trading Hours* (UTC) Opens on Tuesday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.44
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Amgen Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 267.12
Open* 267.39
1-Year Change* 7.09%
Day's Range* 264.39 - 268.62
52 wk Range 211.71-311.05
Average Volume (10 days) 2.38M
Average Volume (3 months) 49.37M
Market Cap 162.96B
P/E Ratio 21.64
Shares Outstanding 535.18M
Revenue 26.83B
EPS 14.07
Dividend (Yield %) 2.95576
Beta 0.61
Next Earnings Date Feb 6, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 15, 2024 265.25 -2.85 -1.06% 268.10 270.27 264.09
Apr 12, 2024 267.12 -1.33 -0.50% 268.45 268.78 266.03
Apr 11, 2024 269.88 0.73 0.27% 269.15 272.72 268.21
Apr 10, 2024 266.20 -1.57 -0.59% 267.77 267.77 264.19
Apr 9, 2024 270.27 0.72 0.27% 269.55 271.16 268.38
Apr 8, 2024 269.01 1.36 0.51% 267.65 270.03 267.14
Apr 5, 2024 269.87 4.86 1.83% 265.01 272.96 263.98
Apr 4, 2024 267.89 -7.82 -2.84% 275.71 276.48 267.70
Apr 3, 2024 274.31 -0.75 -0.27% 275.06 276.29 273.53
Apr 2, 2024 276.01 -6.18 -2.19% 282.19 283.34 275.96
Apr 1, 2024 282.97 1.17 0.42% 281.80 283.43 278.80
Mar 28, 2024 284.16 -3.28 -1.14% 287.44 288.44 284.08
Mar 27, 2024 286.19 2.64 0.93% 283.55 286.70 282.37
Mar 26, 2024 281.66 -0.44 -0.16% 282.10 284.23 280.47
Mar 25, 2024 280.66 4.79 1.74% 275.87 281.27 274.83
Mar 22, 2024 275.96 -1.10 -0.40% 277.06 278.15 274.99
Mar 21, 2024 276.79 2.79 1.02% 274.00 277.78 274.00
Mar 20, 2024 272.92 3.03 1.12% 269.89 273.01 269.14
Mar 19, 2024 271.62 2.09 0.78% 269.53 273.07 268.75
Mar 18, 2024 270.75 1.27 0.47% 269.48 273.45 268.98

Amgen Events

Time (UTC) Country Event
Thursday, May 2, 2024

Time (UTC)

20:00

Country

US

Event

Q1 2024 Amgen Inc Earnings Release
Q1 2024 Amgen Inc Earnings Release

Forecast

-

Previous

-

Time (UTC)

20:30

Country

US

Event

Q1 2024 Amgen Inc Earnings Call
Q1 2024 Amgen Inc Earnings Call

Forecast

-

Previous

-
Thursday, May 16, 2024

Time (UTC)

12:00

Country

US

Event

Amgen Inc
Amgen Inc

Forecast

-

Previous

-

Time (UTC)

12:00

Country

US

Event

Amgen Inc
Amgen Inc

Forecast

-

Previous

-

Time (UTC)

12:00

Country

US

Event

Amgen Inc
Amgen Inc

Forecast

-

Previous

-
Friday, May 17, 2024

Time (UTC)

18:00

Country

US

Event

Amgen Inc Annual Shareholders Meeting
Amgen Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Thursday, August 1, 2024

Time (UTC)

10:59

Country

US

Event

Q2 2024 Amgen Inc Earnings Release
Q2 2024 Amgen Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 26323 25979 25424 23362 23747
Revenue 26323 25979 25424 23362 23747
Cost of Revenue, Total 6406 6454 6159 4356 4101
Gross Profit 19917 19525 19265 19006 19646
Total Operating Expense 16679 18340 16285 13688 13404
Selling/General/Admin. Expenses, Total 5414 5368 5730 5150 5332
Research & Development 4434 4819 4207 4116 3737
Unusual Expense (Income) 489 1505 47 292
Other Operating Expenses, Total -64 194 189 19 -58
Operating Income 9644 7639 9139 9674 10343
Interest Income (Expense), Net Non-Operating -1406 -1197 -1006 -536 -798
Net Income Before Taxes 7346 6701 8133 9138 9545
Net Income After Taxes 6552 5893 7264 7842 8394
Net Income Before Extra. Items 6552 5893 7264 7842 8394
Net Income 6552 5893 7264 7842 8394
Income Available to Common Excl. Extra. Items 6552 5893 7264 7842 8394
Income Available to Common Incl. Extra. Items 6552 5893 7264 7842 8394
Diluted Net Income 6552 5893 7264 7842 8394
Diluted Weighted Average Shares 541 573 590 609 665
Diluted EPS Excluding Extraordinary Items 12.1109 10.2845 12.3119 12.8769 12.6226
Dividends per Share - Common Stock Primary Issue 7.76 7.04 6.4 5.8 5.28
Diluted Normalized EPS 12.9171 12.911 12.3119 12.9431 13.0087
Total Extraordinary Items
Other, Net -892 259
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 6986 6105 6839 6652 6594
Revenue 6986 6105 6839 6652 6594
Cost of Revenue, Total 1769 1682 1747 1588 1510
Gross Profit 5217 4423 5092 5064 5084
Total Operating Expense 4302 4071 4609 3914 4418
Selling/General/Admin. Expenses, Total 1294 1258 1572 1287 1327
Research & Development 1113 1058 1324 1112 1039
Other Operating Expenses, Total 57 7 -36 -18
Operating Income 2684 2034 2230 2738 2176
Interest Income (Expense), Net Non-Operating -752 -543 -415 -368 -328
Other, Net -318 1951 -67 22 -317
Net Income Before Taxes 1614 3442 1748 2392 1531
Net Income After Taxes 1379 2841 1616 2143 1317
Net Income Before Extra. Items 1379 2841 1616 2143 1317
Net Income 1379 2841 1616 2143 1317
Income Available to Common Excl. Extra. Items 1379 2841 1616 2143 1317
Income Available to Common Incl. Extra. Items 1379 2841 1616 2143 1317
Diluted Net Income 1379 2841 1616 2143 1317
Diluted Weighted Average Shares 537 538 538 538 537
Diluted EPS Excluding Extraordinary Items 2.56797 5.28067 3.00372 3.98327 2.45251
Dividends per Share - Common Stock Primary Issue 2.13 2.13 1.94 1.94 1.94
Diluted Normalized EPS 2.67775 5.38193 3.00715 3.86171 3.34958
Unusual Expense (Income) 69 66 2 -73 560
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 22186 19385 21144 18440 37618
Cash and Short Term Investments 9305 8037 10647 8911 29304
Cash & Equivalents 7629 7989 6266 6037 6945
Short Term Investments 1676 48 4381 2874 22359
Total Receivables, Net 6392 5839 5324 4057 3580
Accounts Receivable - Trade, Net 5563 4895 4525 4057 3580
Total Inventory 4930 4086 3893 3584 2940
Other Current Assets, Total 355 200 124 1888 1794
Total Assets 65121 61165 62948 59707 66416
Property/Plant/Equipment, Total - Net 6006 5750 5297 5397 4958
Property/Plant/Equipment, Total - Gross 15289 14548 14274 13754 12754
Accumulated Depreciation, Total -9283 -8798 -8977 -8357 -7796
Goodwill, Net 15529 14890 14689 14703 14699
Intangibles, Net 16080 15182 16587 19413 7443
Long Term Investments 249 573 1176
Other Long Term Assets, Total 5071 5385 4055 1754 1698
Total Current Liabilities 15687 12184 11653 12835 13488
Accounts Payable 1572 1366 1421 1371 1207
Accrued Expenses 10192 8947 8295 7565 6948
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1591 87 91 2953 4419
Other Current Liabilities, Total 2332 1784 1846 946 914
Total Liabilities 61460 54465 53539 50034 53916
Total Long Term Debt 37354 33222 32895 26950 29510
Long Term Debt 37354 33222 32895 26950 29510
Deferred Income Tax 606 864
Other Liabilities, Total 8419 9059 8991 9643 10054
Total Equity 3661 6700 9409 9673 12500
Common Stock 32514 32096 31802 31531 31246
Retained Earnings (Accumulated Deficit) -28622 -24600 -21408 -21330 -17977
Unrealized Gain (Loss) 1 22 -338
Other Equity, Total -231 -796 -986 -550 -431
Total Liabilities & Shareholders’ Equity 65121 61165 62948 59707 66416
Total Common Shares Outstanding 534 558.3 578.3 591.4 629.6
Prepaid Expenses 1204 1223 1156
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 48477 47380 44703 22186 24062
Cash and Short Term Investments 34741 34248 31561 9305 11478
Cash & Equivalents 34741 34248 31560 7629 9502
Short Term Investments 0 0 1 1676 1976
Total Receivables, Net 6145 5830 5736 5563 5326
Accounts Receivable - Trade, Net 6145 5830 5736 5563 5326
Total Inventory 5026 4978 5011 4930 4757
Other Current Assets, Total 2565 2324 2395 2388 2501
Total Assets 90534 90269 88720 65121 63700
Property/Plant/Equipment, Total - Net 5563 5532 5460 5427 5188
Goodwill, Net 15509 15531 15531 15529 14845
Intangibles, Net 13150 14633 15393 16080 13266
Other Long Term Assets, Total 7835 7193 7633 5899 6339
Total Current Liabilities 16954 17097 14215 15687 14331
Accounts Payable 1358 1212 1320 1572 1204
Accrued Expenses 14168 13718 12061 12524 11584
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1428 2167 834 1591 1543
Total Liabilities 82878 83488 83372 61460 60047
Total Long Term Debt 59040 59377 60761 37354 37161
Long Term Debt 59040 59377 60761 37354 37161
Other Liabilities, Total 6884 7014 8396 8419 8555
Total Equity 7656 6781 5348 3661 3653
Common Stock 32753 32601 32535 32514 32371
Retained Earnings (Accumulated Deficit) -24971 -25540 -26919 -28622 -28066
Unrealized Gain (Loss)
Other Equity, Total -126 -280 -268 -231 -652
Total Liabilities & Shareholders’ Equity 90534 90269 88720 65121 63700
Total Common Shares Outstanding 535.1 534.9 534.3 534 533.5
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 6552 5893 7264 7842 8394
Cash From Operating Activities 9721 9261 10497 9150 11296
Cash From Operating Activities 3417 3398 3601 2206 1946
Deferred Taxes -1198 -453 -287 -289 -363
Non-Cash Items 1683 1617 135 122 697
Cash Taxes Paid 2400 1900 1400 1900 1900
Cash Interest Paid 1200 1200 1200 1300 1500
Changes in Working Capital -733 -1194 -216 -731 622
Cash From Investing Activities -6044 733 -5401 5709 14339
Capital Expenditures -936 -880 -608 -618 -738
Other Investing Cash Flow Items, Total -5108 1613 -4793 6327 15077
Cash From Financing Activities -4037 -8271 -4867 -15767 -22490
Financing Cash Flow Items -400 -78 -90 -42 -68
Total Cash Dividends Paid -4196 -4013 -3755 -3509 -3507
Issuance (Retirement) of Stock, Net -6360 -4975 -3486 -7702 -17794
Issuance (Retirement) of Debt, Net 6919 795 2464 -4514 -1121
Net Change in Cash -360 1723 229 -908 3145
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 2841 6552 4936 2793 1476
Cash From Operating Activities 1064 9721 7072 4094 2164
Cash From Operating Activities 900 3417 2506 1669 841
Deferred Taxes -49 -1198 -847 -514 -251
Non-Cash Items -1874 1683 1514 1493 545
Changes in Working Capital -754 -733 -1037 -1347 -447
Cash From Investing Activities 1358 -6044 -2571 -2304 -111
Capital Expenditures -344 -936 -596 -436 -190
Other Investing Cash Flow Items, Total 1702 -5108 -1975 -1868 79
Cash From Financing Activities 21509 -4037 -2988 -4576 -3514
Financing Cash Flow Items -448 -400 -410 -52 -26
Total Cash Dividends Paid -1137 -4196 -3156 -2118 -1080
Issuance (Retirement) of Stock, Net 0 -6360 -6360 -6360 -6360
Issuance (Retirement) of Debt, Net 23094 6919 6938 3954 3952
Net Change in Cash 23931 -360 1513 -2786 -1461

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Amgen Company profile

About Amgen, Inc.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Amgen, Inc. revenues increased 2% to $25.98B. Net income decreased 19% to $5.89B. Revenues reflect Other revenues segment increase of 42% to $1.68B, Prolia segment increase of 18% to $3.25B, ROW segment increase of 12% to $7.01B, Other revenues segment increase of 42% to $1.68B. Net income was offset by Research and development increase of 15% to $4.82B (expense), Other increase of 3% to $194M (expense).

Equity composition

Common Stock $.0001 Par, 4/11, 2.75B auth., 929,730,507 issd. Insiders own 0.12% . IPO 5/87, 2M shares @ $34 by Paine Webber. 9/91, 3-for-1 split; 11/99, 3/99, 8/95, 7/90, 2-for-1 splits. 7/02, Company acquired Immunex Corp. @ $4.50/share and 0.44 shs. (242,916,735 shs. issd.).

Industry: Pharmaceuticals (NEC)

One Amgen Center Drive
THOUSAND OAKS
CALIFORNIA 91320-1799
US

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

BTC/USD

63,188.10 Price
-0.730% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

17,668.70 Price
-1.850% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

3,078.51 Price
+0.740% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Gold

2,387.73 Price
+1.860% 1D Chg, %
Long position overnight fee -0.0187%
Short position overnight fee 0.0105%
Overnight fee time 21:00 (UTC)
Spread 0.50

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading